moclobemide
Trade name: Amira
Moclobemide, sold under the brand names Amira, Aurorix, Clobemix, Depnil and Manerix among others, is a reversible inhibitor of monoamine oxidase A (RIMA) drug primarily used to treat depression and social anxiety. It is not approved for use in the United States, but is approved in other Western countries such as Canada, the UK and Australia. It is produced by affiliates of the Hoffmann–La Roche pharmaceutical company. Initially, Aurorix was also marketed by Roche in South Africa, but was withdrawn after its patent rights expired and Cipla Medpro's Depnil and Pharma Dynamic's Clorix became available at half the cost. — Wikipedia
Clinical trial activity
5 trials · 8 clinical orgs · 0 marketing orgs
Earliest trial started Nov 1, 2008 (NCT00534573)
Timeline
Indications
Mechanism of action
- Monoamine oxidase AINHIBITOR
MAOA inhibitor
Chemistry & pharmacology
SMILES
O=C(NCCN1CCOCC1)c1ccc(Cl)cc1- Mol. weight
- 268.74 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaMoclobemide ↗
- ChEMBLCHEMBL86304 ↗
Also known as
- 4-chlor-n-(2-morpholinoethyl)benzamid
- 4-chlor-n-(2-morpholinoethyl)benzamid
- 4-chloro-n-(2-(4-morpholinyl)ethyl)benzamide
- 4-chloro-n-(2-(4-morpholinyl)ethyl)benzamide
- 4-chloro-n-(2-morpholin-4-yl-ethyl)-benzamide
- 4-chloro-n-(2-morpholin-4-yl-ethyl)-benzamide
- auromid
- aurorix
- aurorix
- aurorix
- gnf-pf-695
- gnf-pf-695
- manerix
- manerix
- moclaime
- moclaime
- moclaime
- moclamide
- moclamide
- moclamine
- moclamine
- moclobamide
- moclobamide
- moclobamide
- moclobamide
- moclobamide
- moclobamide
- moclobemid
- moclobemid
- moclobemida
- moclobemida
- moclobemide
- moclobemide
- moclobemide
- moclobemide
- moclobemide
- moclobemide
- moclobemide
- moclobemidum
- moclobemidum
- p-chloro-n-(2-morpholinoethyl)benzamide
- p-chloro-n-(2-morpholinoethyl)benzamide
- ro-111163000
- ro-111163000
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03010761 | Phase 2 | Jan 1, 2016 | China Medical University |
| NCT02374567 | Phase 3 | Jan 1, 2015 | Gottfried Wilhelm Leibniz Universität Hannover |
| NCT02269540 | Early Phase 1 (Phase 1) | Oct 1, 2014 | University of Toronto |
| NCT01926626 | Phase 2 | Sep 1, 2013 | Duke University, National Institute on Drug Abuse (NIDA), Philip Morris |
| NCT00534573 | Phase 3 | Nov 1, 2008 | Ben Gurion University, Technion University |
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ben Gurion University | Academic/Hospital | 1 | 1 | 1 | 2008 |
| China Medical University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Gottfried Wilhelm Leibniz Universität Hannover | Academic/Hospital | 1 | 1 | 1 | 2015 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2013 |
| Philip Morris | For profit | 1 | 0 | 1 | 2013 |
| Technion University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2014 |